目的 :观察恶性淋巴增殖性疾病肿瘤细胞表面 β2 整合素 (CD11a、CD11b)及L 选择素 (CD6 2L)的表达变化及其临床意义。方法 :用流式细胞仪检测 35例初诊或复发急性淋巴白血病 (ALL)、4例慢性淋巴细胞白血病 (CLL)、30例多发性骨髓瘤 (MM)、14例淋巴肉瘤白血病及 2 5例正常人骨髓单个核细胞粘附分子CD11a、CD11b、CD6 2L的表达。结果 :①与正常造血细胞比较 ,CD11b、CD11a在ALL、MM、CLL细胞表达均下降 (P <0 0 1) ,但在淋巴肉瘤白血病细胞表达无明显改变 (P >0 0 5 ) ,CD6 2L在MM、CLL、淋巴肉瘤白血病细胞表达均下降 (P <0 0 5 ) ,但在ALL中表达增强 (P <0 0 5 )。②CD11a在ALL表达明显高于淋巴肉瘤白血病细胞表达 (P <0 0 1) ,CD6 2L在ALL表达明显低于淋巴肉瘤白血病细胞 (P <0 0 1)。③浸润组CD11a在ALL表达高于非浸润组 ,(P <0 0 5 )。④ALL完全缓解组CD11a、CD11b的表达可升至正常范围。结论 :恶性淋巴增殖性疾病肿瘤细胞表面上存在多个粘附分子的表达异常 ,检测粘附分子有助于判断白血病细胞类型及疗效。 Objective: To observe the expression and clinical significance of β2 integrin (CD11a, CD11b) and L-selectin (CD6 2L) on tumor cell surface of malignant lymphoproliferative diseases. METHODS: Fifty-five newly diagnosed or relapsed acute lymphocytic leukemia (ALL), 4 chronic lymphocytic leukemia (CLL), 30 multiple myeloma (MM), 14 lymphosarcoma cases, and 25 normal cases were detected by flow cytometry Human bone marrow mononuclear cell adhesion molecules CD11a, CD11b, CD6 2L expression. RESULTS: 1Compared with normal hematopoietic cells, the expression of CD11b and CD11a in ALL, MM, and CLL cells decreased (P < 0.01), but there was no significant change in lymphoid sarcoma leukemia cells (P > 0.05). CD6 2L The expression of MM, CLL, lymphosarcoma leukemia cells was decreased (P < 0.05), but increased in ALL (P <0 05). 2 The expression of CD11a in ALL was significantly higher than that in lymphoid sarcoma leukemia cells (P < 0 01). The expression of CD6 2L in ALL was significantly lower than that of lymphosarcoma leukemia cells (P <0 01). 3 The expression of CD11a in the infiltrating group was higher than that in the non-infiltrating group (P<0 05). The expression of CD11a and CD11b in the 4 ALL complete remission group rose to the normal range. Conclusion : Abnormal expression of multiple adhesion molecules exists on the surface of malignant lymphoproliferative tumor cells. The detection of adhesion molecules is helpful to determine the type and efficacy of leukemia cells.